Notes: RPI-1 is an ATP-dependent RET kinase inhibitor. It has been shown to selectively inhibit the anchorage-independent growth of NIH3T3 cells transformed by the ret/ptc1 oncogene with an IC50 value of 0.97 µM.{32109} In a spontaneously metastasizing lung carcinoma xenograft mouse model, daily oral treatment with RPI-1 was reported to significantly reduce spontaneous lung metastases.{32108}